Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Leases (2019 - 2025)

Arcturus Therapeutics Holdings' Current Leases history spans 7 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Current Leases rose 18.64% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 18.64%, while the annual FY2025 figure was $4.2 million, 18.64% up from the prior year.
  • Current Leases reached $4.2 million in Q4 2025 per ARCT's latest filing, up from $4.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $4.3 million in Q4 2023 to a low of $1.4 million in Q2 2021.
  • Average Current Leases over 5 years is $3.3 million, with a median of $3.8 million recorded in 2022.
  • Peak YoY movement for Current Leases: surged 155.09% in 2022, then decreased 18.21% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.5 million in 2021, then skyrocketed by 152.7% to $3.9 million in 2022, then rose by 10.94% to $4.3 million in 2023, then decreased by 17.57% to $3.6 million in 2024, then rose by 18.64% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Current Leases are $4.2 million (Q4 2025), $4.1 million (Q3 2025), and $4.0 million (Q2 2025).